ent in primary human target cells (Bailey et al., 2014, de Lang et al., 2006, Sainz et al., 2004, Zheng et al., 2004). One study of SARS-CoV suggested the timing of the type I IFN response was critical in vivo (Channappanavar et al., 2016). Clinical therapy using ap